Why has there been a global surge of new Covid variant NB.1.8.1?
Cases have now been reported in Asian countries such as Thailand, Indonesia and China, while the UK Health Security Agency recorded the first 13 cases in England last week.
But the true numbers are unlikely to be known, given the significant decrease in the number of people testing compared to the figures seen during the global pandemic five years ago.
NB.1.8.1 stemmed from the Omicron variant and was first detected in January this year.
It has quickly spread across China and Hong Kong, and has now been recorded in several states across the United States and Australia.
By late April, NB.1.8.1 comprised about 10.7 per cent of submitted sequences globally, according to the World Health Organization (WHO). This rose from just 2.5 per cent a month before.
The WHO declared the NB.1.8.1 strain a 'variant under monitoring' on 23 May, which means scientists believe it could potentially affect the behaviour of the virus.
Lara Herrero, a virologist from Griffith University in Australia, suspects that NB.1.8.1 spreads more easily than other variants.
'Using lab-based models, researchers found NB.1.8.1 had the strongest binding affinity to the human ACE2 receptor of several variants tested, suggesting it may infect cells more efficiently than earlier strains,' Dr Herrero wrote last month in The Conversation.
Dr Chun Tang, GP at UK private healthcare centre Pall Mall Medical, said: 'NB.1.8.1 isn't too different from the Omicron variant, but it does have some tweaks to its spike protein, which might make it spread a bit more easily or slip past some of our existing immunity.
'That said, early signs suggest it doesn't seem to cause more serious illness, but of course, we're still learning more about it.'
'Its spread has been identified in around 22 countries,' said Dr Naveed Asif, GP at The London General Practice.
'The WHO assesses the additional risk to the global public as currently low, and existing Covid-19 vaccines are considered effective in preventing severe disease.'
However, the 'Nimbus' variant, as it has been dubbed, does appear to be more transmissible than previous strains, with notable increases reported in India, Hong Kong, Singapore and Thailand, notes Dr Asif.
Common symptoms of Nimbus include a severe sore throat, fatigue, mild cough, fever, muscle aches and congestion.
It has also been reported that some patients have experienced gastrointestinal symptoms such as nausea and diarrhoea.
Healthcare experts have stressed, however, that there is no evidence that the new strain is more deadly or serious than previous variants, and that current Covid vaccines are expected to remain effective and protect anyone infected from severe illness.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
2 hours ago
- Boston Globe
A debilitating mosquito-borne virus spreads to more regions of the world
The World Health Organization is warning that current transmission patterns resemble a global outbreak that infected 500,000 people 20 years ago, contributing to a surge of new disabilities. Advertisement Although it is rarely fatal, chikungunya causes excruciating and prolonged joint pain and weakness. 'You have people who were working, with no disabilities, and from one day to the next, they cannot even type on a phone, they can't hold a pen, a woman cannot even hold a knife to be able to cook for her family,' said Dr. Diana Rojas Alvarez, who leads chikungunya work at the WHO. 'It really impacts quality of life and also the economy of the country.' A worker sprayed insecticide to prevent the spread of Chikungunya in Guangdong Province, China, on Aug. 3. VCG/Getty Images What is chikungunya, and how dangerous is it? Like Zika and dengue fever, chikungunya is an RNA virus transmitted by mosquitoes. Two different species of mosquitoes, Aedes aegypti and Aedes albopictus, transmit chikungunya. Between four and eight days after a bite, a person can develop symptoms including fever, joint pain and a rash. Advertisement Unlike dengue and Zika infections, the majority of which are asymptomatic, chikungunya sickens most people it infects. In rare instances, chikungunya can kill young children and older adults. 'Fatality levels are low, but we really care about chikungunya because it leaves people with months or potentially years of debilitating pain,' said Scott Weaver, an expert and the scientific director of the Galveston National Laboratory in Texas. He added: 'That has not only an individual toll but also a social one, with strain on health care systems, economic impact, the demand on caregivers, a lot of things.' Chikungunya is often misdiagnosed as dengue, which causes the same symptoms at first. Dengue symptoms usually clear up in a week or two; chikungunya symptoms become chronic in as many as 40% of people infected, with debilitating joint pain lasting for months or years. Between 2005 and 2007, more than two-thirds of all the disabilities -- including those caused by cancer, arthritis and diabetes -- reported in India were the result of a chikungunya outbreak that was sweeping through the country. A vaccination against on La Reunion on April 7. RICHARD BOUHET/AFP via Getty Images Who is at risk? By the end of 2024, transmission of the virus had been reported in 199 countries, on every continent except Antarctica. The WHO estimates that 5.6 billion people live in areas where the mosquitoes that transmit the virus can live. These mosquitoes are daytime biters, feeding on people who are at work, at school or on a bus. Climate change is driving the spread of chikungunya-carrying mosquitoes in two ways. A warmer, wetter world provides more suitable habitat. And extreme weather events can cause more breeding in floods -- or displace people, who cluster in areas with poor water and sanitation supply. Advertisement The Aedes albopictus mosquito has markedly expanded its presence in Europe in recent years: The insect has been found in Amsterdam and Geneva. In South America, Aedes aegypti carries the virus and thrives in low-income neighborhoods in rapidly growing cities with patchy water systems. 'In the U.S. I don't think we're going to see massive outbreaks of chikungunya' because people in warm areas use air conditioning and spend a lot of time indoors, Weaver said. 'But in places like China and the Southern Cone of South America, the warming temperatures are going to have a big impact because people don't stay inside with air conditioners in their houses or their workplaces. They don't even like to screen their windows in many parts of Asia and South America.' People seem to become immune to chikungunya after an infection and so, if it sweeps through an area, it can be a couple of decades before there are enough immunologically vulnerable people to sustain another outbreak. But in places such as India and Brazil, populations are so large that the virus is circulating constantly. Many countries in Africa that did not have circulating chikungunya, such as Chad and Mali, have reported cases in the past few years. Residents walked past a sign urging mosquito control in Guangzhou, China, on Aug. 6, 2025. The message reads, "Let's work together to clear stagnant water and eliminate mosquito breeding". Uncredited/Associated Press Is there a vaccine? There are two vaccines for chikungunya, but they are produced in limited quantities for use mainly by travelers from industrialized countries. The newest vaccine, made by Bavarian Nordic, sells for about $270 per shot in the United States, a price well beyond the reach of a country such as Paraguay, which has had huge chikungunya outbreaks and would ideally vaccinate much of the population. Brazil's Butantan Institute is working on making a lower-cost version of another vaccine. Advertisement Neither vaccine currently has the kind of WHO recommendation that might lead to accelerated development of an affordable product. Doing a clinical trial of the kind the agency requires is difficult: Chikungunya outbreaks happen so fast that they're over before the research can begin. Rojas said the WHO's vaccine committee was reviewing chikungunya outbreak data to consider options for a possible recommendation. What else can be done? The best protection against chikungunya is not to get bitten. The next step is to reduce mosquito breeding sites. In China, public health officials are going house to house to look for stagnant water. Surveillance for chikungunya is still weak. Rojas said the WHO was trying to untangle how much of the current surge was new cases and how much was transmission that was already occurring but poorly tracked or reported. There is a molecular diagnostic test that screens for Zika, dengue and chikungunya at the same time, but more countries need to adopt it. Disease surveillance globally has been weakened by the abrupt cuts in funding from the U.S. government, which was supporting much of this work in low-income countries. Is this a new virus? Chikungunya was first identified in Tanzania in the 1950s, and caused sporadic outbreaks in Africa and Asia in the next decades. But the virus didn't attract much attention from public health specialists until 2004. That year, an outbreak in Kenya spread to La Réunion, a French territory in the Indian Ocean. There, chikungunya raged through the population: One-third of the people on the island were infected. Advertisement That same strain of the virus made its way to South Asia, and caused huge outbreaks in India from 2005 to 2007. And from there travelers took chikungunya around the world. By late 2013, the virus had made its way to the Caribbean and once again began to tear through a population that lacked immunity. There were 1.8 million reported infections in the region by the end of 2015. Chikungunya then made its way down through South America -- and a new strain from Angola was introduced to Brazil at the same time -- and the two have been circulating since then. Chikungunya cases in South America have risen steadily since 2023, alongside a surge in dengue cases. This article originally appeared in
USA Today
3 hours ago
- USA Today
US pediatric group breaks with CDC advice, recommends COVID vaccines for young children
The American Academy of Pediatrics released its vaccine recommendations on Aug. 19 in a break from federal guidance shaped by Health and Human Services Secretary Robert F. Kennedy Jr. The AAP, in tandem with multiple other professional medical associations, previously decried a May announcement made by Kennedy Jr. that the COVID-19 vaccine would no longer be included in the Centers for Disease Control's recommended immunizations for healthy children and pregnant women, a move that went against previous expert guidance and bypassed the normal scientific review process. The AAP, a professional organization of over 65,000 board-certified pediatricians dedicated to advancing children's medicine, said in a June 26 statement that it would "continue to publish its own evidence-based recommendations and schedules," as the creation of federal immunization policy is 'no longer a credible process." Kennedy Jr. drew further ire from medical communities when he fired all 17 original members of the Advisory Committee on Immunization Practices, the committee of health experts that provides guidance on vaccine use to the CDC, replacing them with members that critics have called unqualified. Some of the members, like Kennedy Jr., have a history of anti-vaccine advocacy and involvement in anti-vaccine groups. Here's what to know about the new AAP guidance and how it differs from federal guidelines. What is the AAP guidance on COVID-19 vaccines for children? The AAP schedule lists which vaccines children should get at certain ages and provides updated guidance on influenza, RSV, and COVID-19 immunizations for children and adolescents from birth to age 18. The schedule recommends that all children between six months and 23 months receive the latest COVID-19 vaccine to reduce the chance of serious illness. Children and adolescents aged 2 to 18, without other high-risk factors like immunosuppression, can receive and should be offered the vaccine if they were not previously immunized, according to the guidance. Children, teens, and adults alike who are at increased risk of serious infection should receive the vaccine if they have not already, AAP said, adding that its recommendation differed from the CDC, which it said is now staffed with people who have a history of spreading vaccine misinformation. "The AAP will continue to provide recommendations for immunizations that are rooted in science and are in the best interest of the health of infants, children, and adolescents," AAP President Dr. Susan J. Kressly, MD, said in a statement. "Pediatricians know how important routine childhood immunizations are in keeping children, families and their communities healthy and thriving." What is the federal guidance on COVID-19 vaccines for children? The CDC did not go as far as completely removing COVID-19 vaccination from its immunization schedule despite Kennedy Jr.'s insistence. Instead, the agency changed its language from recommending the vaccine annually to suggesting parents consult with their child's physician on whether to vaccinate. Kennedy Jr. previously said that the CDC planned only to recommend the COVID vaccine for people over the age of 65 and those at high personal risk of infection, though the agency's website still contains information recommending it for everyone over the age of six months. A notice on the top webpages on the topic reads, "COVID-19 vaccine recommendations have recently been updated for some populations. This page will be updated to align with the updated immunization schedule," as of Aug. 19. This change to whom the vaccine is recommended could make it harder for others who want the COVID-19 vaccine to get it, experts warned. Since insurance coverage typically follows federal recommendations, anyone who wants the shot but isn't on the CDC's recommendation list may have to pay the price out of pocket HHS Communications Director Andrew Nixon defended the decision in a statement to USA TODAY, accusing the AAP, which receives funding from pharmaceutical companies like Pfizer, of failing to have proper conflict-of-interest safeguards in place. "By bypassing the CDC's advisory process and freelancing its own recommendations, while smearing those who demand accountability, the AAP is putting commercial interests ahead of public health and politics above America's children," Nixon said. Kennedy Jr. shared a separate response on social media on Aug. 19, pointing out that the agency's top donors are four companies that "make virtually every vaccine on the CDC recommended childhood vaccine schedule" and saying that the AAP recommendations are "corporate-friendly" and may "promote commercial ambitions of AAP's Big Pharma benefactors" instead of public health. "AAP should also be candid with doctors and hospitals that recommendations that diverge from the CDC's official list are not shielded from liability under the 1986 Vaccine Injury Act," his post concluded. USA TODAY reached out to AAP for comment on Aug. 19 but has not received a response. The new Advisory Committee on Immunization Practices didn't vote on COVID-19 vaccine recommendations when they met in June and are expected to reconvene in "September/October," according to the CDC. The FDA has signaled intentions to revoke the Pfizer COVID-19 shot for young, healthy children. In early August, HHS announced that it would pull $500M in funding from mRNA vaccine research and development.
Politico
3 hours ago
- Politico
RFK Jr. attacks pediatricians' group over vaccine recommendations
In May, the Centers for Disease Control and Prevention dropped its recommendation that all children 6 months and older get Covid shots. Kennedy at the time said the move was based on 'common sense' and 'good science. ' The AAP, however, said it had retained its guidance for young children to get the shots because they are still at risk of severe cases of the disease. 'COVID-19 continues to result in hospitalization and death in the pediatric population,' the group said in a release explaining its recommendations, adding that 'children younger than 2 years old are especially vulnerable to severe COVID-19 and should be prioritized for vaccination.' The pediatric group did not immediately respond to POLITICO's request for comment regarding Kennedy's remarks. Earlier Tuesday, HHS spokesperson Andrew Nixon accused the pediatricians of 'freelancing its own recommendations, while smearing those who demand accountability' in a statement to POLITICO. AAP President Susan J. Kressly defended her group's guidance in response, saying they were 'based only in the science, the needs of children, and the care that pediatricians have for the children in every community.' Despite the disagreement over vaccination of young children, both the new CDC guidance and the pediatricians continue to recommend shots for children with underlying conditions that could put them at risk for severe disease. Both have also scaled back recommendations for healthy children older than 6 months, saying that parents of children without underlying conditions should decide on vaccination in consultation with their pediatrician . Why it matters: The pediatricians' split with the CDC underscores the depth of the distrust between the medical establishment and Kennedy — a longtime vaccine skeptic who once said the Covid vaccine was 'the deadliest vaccine ever made' in defiance of scientific consensus.
